ArticleFrontiers in oncology2019
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Multidisciplinary consensus on the criteria for fertility preservation in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Guideline
- Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2021Pooled it
- Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Pooled it
- Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Ovarian reserve in premenopausal women with breast cancer.Breast (Edinburgh, Scotland) · 2022Trial
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Breast Cancer Surgical Risk Reduction, Fertility and Fertility Preservation for Current Breast Cancer Reports.Current breast cancer reports · 2026Review
- Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.Breast cancer research and treatment · 2025Article
- AMH decline during chemotherapy reflects breast cancer cell DNA damage response (DDR) proficiency: the ONCO AMH1 pilot study.Journal of assisted reproduction and genetics · 2025Article
- Early breast cancer in youngTherapeutic advances in medical oncology · 2025Review
- Stratification system for pharmaceutical care in cancer patients: Chinese expert consensus.Frontiers in pharmacology · 2025Article
- Fertility in early breast cancer patients: integrating reproductive planning into oncology care.Frontiers in endocrinology · 2025Review
- Pregnancy after breast cancer: latest evidence and practical considerations.Therapeutic advances in medical oncology · 2025Review
- Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.Current oncology reports · 2024Review
- Review
- Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview.Life (Basel, Switzerland) · 2024Review
- Fertility and Pregnancy-Related Issues in YoungBreast cancer : basic and clinical research · 2024Review
- The Future of Breast Cancer Research in the Survivorship Field.Oncology and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.